_2020091018165303jzv.jpg "Decoding The World Of ETF")
My Account
Partnered by:
Associate Partners:
Partnered by:
Associate Partners:
Oct 14, 2019 03:53 PM IST Net Sales are expected to increase by 5.4 percent Y-o-Y (up 16.5 percent Q-o-Q) to Rs. 1,354.7 crore, according to Emkay.
Jan 18, 2019 02:40 PM IST Net Sales are expected to increase by 25 percent Y-o-Y (up 1 percent Q-o-Q) to Rs. 1,297.4 crore, according to Sharekhan.
Jan 11, 2019 05:30 PM IST Net Sales are expected to increase by 26.1 percent Y-o-Y (up 1.8 percent Q-o-Q) to Rs. 1,308.2 crore, according to ICICI Direct.
Nov 13, 2018 10:52 AM IST Input cost pressure is being increasingly absorbed by companies as the demand environment in weakening
Oct 17, 2018 05:59 PM IST Net Sales are expected to increase by 15 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 1,020 crore, according to HDFC Securities.
Oct 16, 2018 07:06 PM IST Net Sales are expected to increase by 20 percent Y-o-Y (up 7.3 percent Q-o-Q) to Rs. 1,068.2 crore, according to Sharekhan.
Oct 12, 2018 04:37 PM IST Net Sales are expected to increase by 13.7 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 1,012.4 crore, according to ICICI Direct.
Apr 20, 2018 01:05 PM IST Net Sales are expected to increase by 6.7 percent Y-o-Y (up 9.6 percent Q-o-Q) to Rs. 1,140 crore, according to HDFC Securities.
Oct 30, 2017 06:18 PM IST Revenue may decline due to ongoing USFDA import alert and re-inspection in Q2 of Unit 2.
Jan 27, 2017 04:51 PM IST Street will be squarely focused on commentary on 5 observations co received on its unit 2 by USFDA, inspected from Nov 29 to December 6. Analysts expect the observations to turn either into Warning letter or import alert. Unit 2 accounts for around 70 percent of company's revenue.
Aug 12, 2016 11:18 AM IST Divis Laboratories' first quarter profit seen up 9 percent year-on-year to Rs 265.3 crore and revenue may jump 17 percent to Rs 948 crore, according to a CNBC-TV18 poll.
Jul 16, 2016 01:14 PM IST Sales are expected to decrease by 13.7 percent Q-o-Q (up 16.9 percent Y-o-Y) to Rs 945.1 crore, according to Religare Research.
Jul 14, 2016 06:20 PM IST Net Sales are expected to decrease by 15.1 percent Q-o-Q (up 15.0 percent Y-o-Y) to Rs 929.9 crore, according to Edelweiss
May 27, 2016 05:39 PM IST Topline growth may be on the back of increased capacity utilisation at new SEZ units and generic business. Analysts feel capacity utilisation rates should rise to 80 percent against 75 percent earlier.
Feb 05, 2016 09:44 AM IST Operating profit in Q3 is likely to jump 28.2 percent to Rs 364 crore and margin may expand 240 basis points to 38.4 percent compared to year-ago period.
Jul 11, 2013 11:39 AM IST Nirmal Bang research expects the companies in their coverage universe to post a 4.4% YoY revenue growth, a 1% decline in EBITDA and a 7.2% fall in net profit. The performance reflects demand slowdown in the economy amid a depreciating Indian rupee.
May 23, 2013 01:51 PM IST Sandeep Shenoy of Anand Rathi is bullish on Tech Mahindra and expects the company to perform well ahead. He recommends buying Divis Labs on dips.
Apr 16, 2013 01:30 PM IST Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).
Jan 12, 2013 03:52 PM IST Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).
Jan 12, 2013 11:54 AM IST Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.
Jan 12, 2013 10:57 AM IST Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.
Aug 08, 2012 12:34 PM IST In an interview to CNBC-TV18 Bino Pathiparampil of IIFL shared his expectation from various pharmaceutical companies ahead for their earnings.
Jan 31, 2012 01:18 PM IST In an interview to CNBC-TV18, Praful Borah of Nirmal Bang Institutional Equities speak about Glenmark, Divi's results and gives his outlook going forward.
Jan 14, 2012 01:37 PM IST Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.
Jan 10, 2012 06:34 PM IST Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.
